Skip to main content
NCBI home page
Journal of Psychiatry & Neuroscience: JPN logoLink to Journal of Psychiatry & Neuroscience: JPN
. 1995 Jan;20(1):7–9.

Antidepressant failure: augmentation or substitution?

R T Joffe, A J Levitt
PMCID: PMC1188652  PMID: 7865503

Full text

PDF
7

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beasley C. M., Jr, Bosomworth J. C., Wernicke J. F. Fluoxetine: relationships among dose, response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull. 1990;26(1):18–24. [PubMed] [Google Scholar]
  2. Beasley C. M., Jr, Sayler M. E., Cunningham G. E., Weiss A. M., Masica D. N. Fluoxetine in tricyclic refractory major depressive disorder. J Affect Disord. 1990 Nov;20(3):193–200. doi: 10.1016/0165-0327(90)90144-w. [DOI] [PubMed] [Google Scholar]
  3. Feighner J. P., Boyer W. F., Tyler D. L., Neborsky R. J. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry. 1990 Jun;51(6):222–225. [PubMed] [Google Scholar]
  4. Guscott R., Grof P. The clinical meaning of refractory depression: a review for the clinician. Am J Psychiatry. 1991 Jun;148(6):695–704. doi: 10.1176/ajp.148.6.695. [DOI] [PubMed] [Google Scholar]
  5. Jacobsen F. M. Possible augmentation of antidepressant response by buspirone. J Clin Psychiatry. 1991 May;52(5):217–220. [PubMed] [Google Scholar]
  6. Joffe R. T., Bakish D. Combined SSRI-moclobemide treatment of psychiatric illness. J Clin Psychiatry. 1994 Jan;55(1):24–25. [PubMed] [Google Scholar]
  7. Joffe R. T., Singer W., Levitt A. J., MacDonald C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry. 1993 May;50(5):387–393. doi: 10.1001/archpsyc.1993.01820170065008. [DOI] [PubMed] [Google Scholar]
  8. Kupfer D. J., Frank E., Perel J. M. The advantage of early treatment intervention in recurrent depression. Arch Gen Psychiatry. 1989 Sep;46(9):771–775. doi: 10.1001/archpsyc.1989.01810090013002. [DOI] [PubMed] [Google Scholar]
  9. McGrath P. J., Stewart J. W., Harrison W., Quitkin F. M. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull. 1987;23(1):169–172. [PubMed] [Google Scholar]
  10. Meltzer M. S., Baca L., Turpin J. A., Kalter D. C., Dieffenbach C., Friedman R. M., Gendelman H. E. Regulation of cytokine and viral gene expression in monocytes infected with the human immunodeficiency virus. Pathobiology. 1991;59(4):209–213. doi: 10.1159/000163647. [DOI] [PubMed] [Google Scholar]
  11. Nelson J. C., Jatlow P., Quinlan D. M., Bowers M. B., Jr Desipramine plasma concentration and antidepressant response. Arch Gen Psychiatry. 1982 Dec;39(12):1419–1422. doi: 10.1001/archpsyc.1982.04290120049010. [DOI] [PubMed] [Google Scholar]
  12. Otton S. V., Wu D., Joffe R. T., Cheung S. W., Sellers E. M. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 1993 Apr;53(4):401–409. doi: 10.1038/clpt.1993.43. [DOI] [PubMed] [Google Scholar]
  13. Post R. M. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992 Aug;149(8):999–1010. doi: 10.1176/ajp.149.8.999. [DOI] [PubMed] [Google Scholar]
  14. Quitkin F. M., Rabkin J. G., Stewart J. W., McGrath P. J., Harrison W. Study duration in antidepressant research: advantages of a 12-week trial. J Psychiatr Res. 1986;20(3):211–216. doi: 10.1016/0022-3956(86)90004-x. [DOI] [PubMed] [Google Scholar]
  15. Reimherr F. W., Wood D. R., Byerley B., Brainard J., Grosser B. I. Characteristics of responders to fluoxetine. Psychopharmacol Bull. 1984 Winter;20(1):70–72. [PubMed] [Google Scholar]
  16. Roose S. P., Glassman A. H., Walsh B. T., Woodring S. Tricyclic nonresponders: phenomenology and treatment. Am J Psychiatry. 1986 Mar;143(3):345–348. doi: 10.1176/ajp.143.3.345. [DOI] [PubMed] [Google Scholar]
  17. Schatzberg A. F. Dosing strategies for antidepressant agents. J Clin Psychiatry. 1991 May;52 (Suppl):14–20. [PubMed] [Google Scholar]
  18. Shaw D. M. The practical management of affective disorders. Br J Psychiatry. 1977 May;130:432–451. doi: 10.1192/bjp.130.5.432. [DOI] [PubMed] [Google Scholar]
  19. Stark P., Hardison C. D. A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder. J Clin Psychiatry. 1985 Mar;46(3 Pt 2):53–58. [PubMed] [Google Scholar]
  20. Weilburg J. B., Rosenbaum J. F., Biederman J., Sachs G. S., Pollack M. H., Kelly K. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: a preliminary report. J Clin Psychiatry. 1989 Dec;50(12):447–449. [PubMed] [Google Scholar]
  21. Young S. N. Use of tryptophan in combination with other antidepressant treatments: a review. J Psychiatry Neurosci. 1991 Dec;16(5):241–246. [PMC free article] [PubMed] [Google Scholar]
  22. de Montigny C., Cournoyer G., Morissette R., Langlois R., Caillé G. Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Correlations with the neurobiologic actions of tricyclic antidepressant drugs and lithium ion on the serotonin system. Arch Gen Psychiatry. 1983 Dec;40(12):1327–1334. doi: 10.1001/archpsyc.1983.01790110069012. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Psychiatry and Neuroscience are provided here courtesy of Canadian Science Publishing

RESOURCES